公开(公告)号：US12129281B2

公开(公告)日：2024-10-29

申请号：US17275967

申请日：2019-09-12

申请人： ABALOS THERAPEUTICS GMBH

发明人： Karl Lang ,  Cornelia Hardt ,  Michael Bergerhausen ,  Hilal Bhat

IPC分类号： C07K14/08 ,  A61K35/76 ,  A61K35/768 ,  A61K45/06 ,  A61P35/00 ,  C07K14/005 ,  C12N7/00

CPC分类号： C07K14/005 ,  A61K35/768 ,  A61K45/06 ,  A61P35/00 ,  C12N7/00 ,  C12N2760/10021 ,  C12N2760/10022 ,  C12N2760/10032 ,  C12N2760/10052 ,  C12N2760/10071

摘要： The invention relates to a mutant of an arenavirus having improved antitumoral properties. The invention also relates to a method of generating such an arenavirus mutant, related pharmaceutical compositions, medical uses, methods of treatment, and isolated proteins and nucleic acids.

公开(公告)号：US20240350422A1

公开(公告)日：2024-10-24

申请号：US18580090

申请日：2022-07-25

申请人： The Regents of the University of California

发明人： Nicole F. Steinmetz ,  Matthew D. Shin

IPC分类号： A61K9/51 ,  A61K35/76

CPC分类号： A61K9/5184 ,  A61K9/5192 ,  A61K35/76

摘要： Proteinaceous nanoparticles can be used to deliver large payloads of active ingredients, which is advantageous in medicine and agriculture. However, the conjugation of hydrophobic ligands to hydrophilic nanocarriers such as plant viral nanoparticles (plant VNPs) can result in aggregation by reducing overall solubility. Provided herein are improved methods for ligand conjugations, as well as the particles prepared by these methods. The disclosed methods promote efficient bioconjugation and prevent the aggregation that accompanies conventional bioconjugation methods, thus improving the stability, homogeneity, and translational potential of plant VNP conjugates in medicine and agriculture.

公开(公告)号：US20240342230A1

公开(公告)日：2024-10-17

申请号：US18427221

申请日：2024-01-30

申请人： FERRING B.V. ,  INSTITUT PASTEUR

发明人： Pascal Danglas ,  Laurent Debarbieux

IPC分类号： A61K35/76 ,  A61K9/00 ,  C12N7/00

CPC分类号： A61K35/76 ,  A61K9/0053 ,  C12N7/00 ,  C12N2795/10021 ,  C12N2795/10132 ,  C12N2795/10171 ,  Y02A50/30

摘要： The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease.
The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject.
The subject invention also provides new bacteriophage strains.

公开(公告)号：US12114664B2

公开(公告)日：2024-10-15

申请号：US17043847

申请日：2019-02-19

申请人： Intron Biotechnology, Inc.

发明人： Seong Jun Yoon ,  Soo Youn Jun ,  Jee Soo Son ,  Hyoun Rok Paik ,  Beom Seok Kim ,  Sang Hyeon Kang

IPC分类号： C12N7/00 ,  A01N63/40 ,  A23K10/16 ,  A23L2/52 ,  A23L33/10 ,  A61K35/76 ,  A61P31/04

CPC分类号： A01N63/40 ,  A23K10/16 ,  A23L2/52 ,  A23L33/10 ,  A61K35/76 ,  A61P31/04 ,  C12N7/00 ,  A23V2002/00 ,  C12N2795/10321 ,  C12N2795/10331 ,  C12N2795/10332

摘要： The present invention relates to a Siphoviridae bacteriophage STP-2 (Accession number: KCTC 12853BP) isolated from nature and characterized by having the ability to destroy Salmonella Typhimurium and having a genome represented by SEQ ID NO:1; and to a method for preventing and treating diseases caused by Salmonella Typhimurium using Siphoviridae bacteriophage STP-2 containing the same as an active ingredient.

公开(公告)号：US12076352B2

公开(公告)日：2024-09-03

申请号：US16973471

申请日：2019-06-18

申请人： GLAXOSMITHKLINE BIOLOGICALS SA

发明人： Christiane Marie-Paule Simone Jeanne Feron ,  Sandra Giannini

IPC分类号： A61K35/76 ,  C12N7/00

CPC分类号： A61K35/76 ,  C12N7/00 ,  C12N2795/00043 ,  C12N2820/55

摘要： The present invention discloses an engineered bacteriophage capable of binding to a commensal bacterium and inserting its genome polynucleotide into the commensal bacterium, but incapable of producing progeny, incapable of carrying out a lysogenic cycle and incapable of carrying out a lytic cycle within the commensal bacterium, wherein the engineered bacteriophage comprises a genome polynucleotide including at least one gene encoding at least one heterologous antigen(s) under the control of a promoter.

公开(公告)号：US12076351B2

公开(公告)日：2024-09-03

申请号：US16511913

申请日：2019-07-15

申请人： The University of North Carolina at Chapel Hill

发明人： Thomas McCown ,  Steven Gray

IPC分类号： C12N15/86 ,  A61K9/00 ,  A61K35/76 ,  C07K14/005 ,  C12N7/00 ,  A61K39/23 ,  C07K14/015 ,  C12N15/864

CPC分类号： A61K35/76 ,  A61K9/0085 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  A61K39/23 ,  C07K14/015 ,  C12N15/8645 ,  C12N2750/14122 ,  C12N2750/14142 ,  C12N2750/14143 ,  C12N2750/14145 ,  C12N2810/6027

摘要： The invention relates to chimeric AAV capsids targeted to oligodendrocytes and virus vectors comprising the same. The invention further relates to methods of delivering a nucleic acid of interest to an oligodendrocyte in vitro and in vivo, methods of delivering a nucleic acid of interest to an area of the CNS bordering a compromised blood-brain barrier, and methods of treating disorders associated with oligodendrocyte dysfunction using the AAV capsids and virus vectors of the invention.

公开(公告)号：US20240287468A1

公开(公告)日：2024-08-29

申请号：US18570436

申请日：2022-06-14

申请人： Ferring B.V.

发明人： Kristin WANNERBERGER ,  Alexander SULAKVELIDZE

IPC分类号： C12N7/00 ,  A61K35/741 ,  A61K35/76 ,  A61K36/064 ,  A61K39/00 ,  A61K39/09 ,  A61P31/04

CPC分类号： C12N7/00 ,  A61K35/741 ,  A61K35/76 ,  A61K36/064 ,  A61K39/09 ,  A61P31/04 ,  A61K2039/521 ,  C12N2795/00021 ,  C12N2795/00032

摘要： Described herein are bacteriophages that infect and lyse Vancomycin-Resistant Enterococci (VRE). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with Enterococci, including VRE, or who are at risk of infection by Enterococci, including VRE, and for other uses described herein.

公开(公告)号：US20240279620A1

公开(公告)日：2024-08-22

申请号：US18651814

申请日：2024-05-01

申请人： Adaptive Phage Therapeutics, Inc.

发明人： Joseph Robert Fackler ,  Carl Merril ,  Jarrar Haider ,  Viet Dang

IPC分类号： C12N7/00 ,  A61K35/76 ,  A61P31/04 ,  B01D61/20 ,  B01D69/08

CPC分类号： C12N7/00 ,  A61K35/76 ,  A61P31/04 ,  B01D61/20 ,  B01D69/08 ,  B01D2311/2676 ,  B01D2311/2688 ,  B01D2315/10 ,  C12N2795/10132 ,  C12N2795/10151 ,  C12N2795/10232 ,  C12N2795/10251 ,  C12N2795/10332 ,  C12N2795/10351

摘要： A method of recovering viable phage from, for example, a crude phage preparation such as a lysate resulting from amplification of phage in bacterial cell culture is disclosed. The method may be “universal”; that is, applicable to the purification of a broad range of phage species and strains. The phage product resulting from the method may have an acceptably low endotoxin titer (e.g. less than 500 EU/ml) and sufficiently high phage titer (e.g. >1×109 PFU/ml) for use in therapeutic applications.

公开(公告)号：US20240277715A1

公开(公告)日：2024-08-22

申请号：US18565336

申请日：2022-06-01

申请人： Storm Therapeutics Limited

发明人： Oliver Lars Rausch ,  Mark Robert Albertella ,  Yaara Ofir-Rosenfeld ,  Lina Vasiliauskaite

IPC分类号： A61K31/519 ,  A61K31/44 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/553 ,  A61K31/635 ,  A61K31/704 ,  A61K31/706 ,  A61K31/7068 ,  A61K35/76 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02

CPC分类号： A61K31/519 ,  A61K31/44 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/553 ,  A61K31/635 ,  A61K31/704 ,  A61K31/706 ,  A61K31/7068 ,  A61K35/76 ,  A61K39/0011 ,  A61K39/3955 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/4644 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02

摘要： The present invention relates to novel combination therapies for the treatment of proliferative disorders, such as, for example, cancer. The combination therapies comprises the administration of a METTL3 inhibitor in combination with



(i) an immune oncology agent or therapy;
(ii) a BCL2 inhibitor, or a pharmaceutically acceptable salt thereof;
(iii) an anthracycline topoisomerase 2 inhibitor, or a pharmaceutically acceptable salt thereof;
(iv) cytarabine, or a pharmaceutically acceptable salt thereof;
(v) a hypomethylating agent, or a pharmaceutically acceptable salt thereof; or
(vi) a FLT3 inhibitor, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240252611A1

公开(公告)日：2024-08-01

申请号：US18385250

申请日：2023-10-30

申请人： ABALOS THERAPEUTICS GMBH

发明人： Karl Sebastian Lang ,  Halime Kalkavan

IPC分类号： A61K39/12 ,  A61K35/76 ,  A61K35/768 ,  A61K39/00 ,  A61P35/00 ,  C12N7/00

CPC分类号： A61K39/12 ,  A61K35/76 ,  A61K35/768 ,  C12N7/00 ,  A61K2039/5254 ,  A61K2039/585 ,  A61P35/00 ,  C12N2760/10011 ,  C12N2760/10021 ,  C12N2760/10032 ,  C12N2760/10033

摘要： The invention relates to arenaviruses for use in the treatment and/or prevention of tumors and also a method for preparing arenaviruses with (improved) tumor-regressive properties.